SECURA
PharmaSECURA is a pharmaceutical company focused on Oncology. Key products include COPIKTRA.
FDA Novel Drug Designations
(2018)See 1 novel approval →
SECURA's Key Drugs
SECURA's core commercial portfolio centers on COPIKTRA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
SECURA's Recent FDA Approvals
New NDA/BLA approvals for SECURA over the last two years — novel drugs only, excluding generics and label supplements.
SECURA's Therapeutic Areas
SECURA's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SECURA's Top Competitors
SECURA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SECURA Pipeline Snapshot
Active clinical trials for SECURA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • COPIKTRA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling